<DOC>
	<DOCNO>NCT01507051</DOCNO>
	<brief_summary>The study objective investigate pharmacodynamics ( effect drug product ) switch treatment warfarin rivaroxaban . 84 young , healthy subject participate ; treat follow randomize , parallel-group ( Treatments A , B , C ) , placebo-controlled ( Treatment B ) , single-blind ( Treatments A B ) design . The first two group ( A , B ) receive warfarin approximately one week adjust blood coagulation value specific level , i.e . maintain INR ( international normalize ratio ) 2.0 - 3.0 . This range commonly use long-term anticoagulant treatment . The first group ( A ) receive rivaroxaban four day , second group ( B ) take placebo . On last day , subject group A B receive vitamin K neutralize effect warfarin . The third group ( C ) undergo prior treatment warfarin receive rivaroxaban four day .</brief_summary>
	<brief_title>Switching Study From Warfarin Rivaroxaban</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 1</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>18 45 year age ; Normal body weight : BMI ( body mass index ) 18 29 kg/m2 ; Pharmacogenetics : subject homozygous wildtype allele 2C9*1 carrier Callele position 6484 7566 VKORC1 ( vitamin K epoxide reductase ) gene , respectively Relevant deviation normal range clinical examination ; Relevant deviation normal range clinical chemistry , hematology urinalysis ; Resting heart rate awake subject 45 BPM ( beat per minute ) 90 BPM ; Systolic blood pressure 100 mmHg 140 mmHg ; Diastolic blood pressure 85 mmHg ; Relevant pathological change ECG ( electrocardiogram ) second thirddegree AV block , prolongation QRS ( QRS complex ECG ) complex 120 msec QT / QTcinterval 450 msec ( QT interval ECG , QTc interval correct heart rate ) ; Subject test HIV1/2Ab , p24Ag , HbsAg HCVAb positive ; Known coagulation disorder ( e.g . von Willebrand 's disease , haemophiliac ) ; Known disorder increase bleed risk ( e.g . periodontosis , hemorrhoid , acute gastritis , peptic ulcer ) ; Known sensitivity common cause bleeding ( e.g . nasal ) ; Recent plan surgical diagnostic procedure central nervous system ( CNS ) eye ; Subjects hyperlipidemia ( Coumadin / warfarin warn )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Rivaroxaban</keyword>
	<keyword>Xa-Factors</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Embolism</keyword>
</DOC>